日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

CLDN18.2 CAR-derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer

CLDN18.2 CAR衍生细胞外囊泡免疫疗法改善小鼠胰腺癌的预后

Yue Qing ,Ke Jiang ,Hua Jiang ,Yaru Zhao ,Chu-Hu Lai ,Alexandra Aicher ,Zonghai Li ,Christopher Heeschen

Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers

AZD6422(一种靶向CLDN18.2的嵌合抗原受体T细胞)在胃癌、胰腺癌和食管癌中的临床前评估

Allison M Barrett ,Zachary T Britton ,Rosa A Carrasco ,Shannon Breen ,Maria A S Broggi ,Amanda L Hatke ,Benjamin Clark ,Chunning Yang ,Sandrina Phipps ,Lorenzo Ortiz ,Brianna Janocha ,Peter Zanvit ,Nicolas A Giraldo ,Philip L Martin ,Jean-Martin Lapointe ,Nathalie Harder ,Georgina H Cornish ,Bala N N R Attili ,Yariv Mazor ,Melissa Damschroder ,Mark Cobbold ,Gordon Moody ,Emily E Bosco

Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancer

针对胃癌致癌融合基因CLDN18-ARHGAP的免疫疗法

Yue Wang # ,Hanbing Wang # ,Tao Shi # ,Xueru Song ,Xin Zhang ,Yue Zhang ,Xuan Wang ,Keying Che ,Yuting Luo ,Lixia Yu ,Baorui Liu ,Jia Wei

ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models

ZL-1211通过增强ADCC和激活NK细胞介导的炎症反应,在CLDN18.2高表达和低表达的胃癌模型中表现出强大的抗肿瘤活性。

Hiroyasu Konno ,Tracey Lin ,Renyi Wu ,Xinchuan Dai ,Shou Li ,Grace Wang ,Min Chen ,Wenying Li ,Lina Wang ,Bee-Chun Sun ,Zhen Luo ,Tom Huang ,Yuping Chen ,John Zhang ,Qiuping Ye ,David Bellovin ,Bing Wan ,Lishan Kang ,Christopher Szeto ,Karl Hsu ,Omar Kabbarah